Mental Health DailyResearch. Evidence. Perspective.Published research on Drugs.
First-generation antipsychotic (FGA) shortages are not just pharmacy annoyances; they force medication changes in people who may have taken years to stabilize on a tolerable regimen. Researc…
Read articleIceland is a registry-rich country with a small enough population that genuinely nationwide health data is feasible — not the survey-based approximations that anchor most psychiatric epidemi…
Read articlePatients with schizophrenia have substantially elevated dementia risk compared to the general population — roughly 2-3 times the age-adjusted rate — but the specific drivers within the schiz…
Read articleClozapine is the only medication with proven efficacy for treatment-resistant schizophrenia, yet most eligible patients wait years before starting it. A 2026 paper by Perfalk and colleagues …
Read articleMultiple system atrophy is a rapidly progressive neurodegenerative disease with no proven disease-modifying therapy. A 2026 review by Jeong and colleagues tracks two decades of repurposed-dr…
Read articleLurasidone is approved for schizophrenia and bipolar depression on the strength of acute trials that mostly reported a single number: the change in PANSS total score. A 2026 post-hoc analysi…
Read articlePsychedelic-assisted therapy has been one of the most-covered mental-health stories of the past decade. A 2026 quantitative analysis by Evers and colleagues maps how media enthusiasm grew, p…
Read article
